MEI Pharma Inc (MEIP.OQ)
16 Mar 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|65||2015||Independent Chairman of the Board|
|62||2010||President, Chief Executive Officer, Director|
|54||2017||Chief Financial Officer, Secretary|
|52||2014||Senior Vice President of Corporate Development, General Counsel|
|60||2011||Chief Medical Officer|
- BRIEF-Mei Pharma Inc says On Feb 22, Board Voted To Increase Size Of Board By One Seat
- BRIEF-MEI Pharma Says Interim Data Review Supports Continuation Of ME-344 Clinical Study
- BRIEF-MEI Pharma Q2 Loss Per Share $0.16
- BRIEF-Helsinn Group and MEI Pharma's Pracinostat receives orphan drug designation from European Medicines Agency
- BRIEF-MEI Pharma Announces FDA Clearance Of Investigational New Drug Application For CDK Inhibitor Voruciclib